Gene therapy for cardiovascular disease: Perspectives and potential

Vascular Pharmacology

Volumn 58, Issue 3, 2013, Pages 174-181

  Bradshaw, Angela C ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adenovirus; Cardiovascular disease; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; LIPOSOME; MARIMASTAT; MATRIX METALLOPROTEINASE; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 195; MICRORNA 21; MICRORNA 221; MICRORNA 222; PARVOVIRUS VECTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRABEDERSEN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADENOVIRUS 5; AORTA INJURY; ARTICLE; BARE METAL STENT; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG ELUTING STENT; GENE THERAPY; GENE TRANSFER; GLIOMA; GRAFT FAILURE; HEART FAILURE; HUMAN; IMMUNOGENICITY; IN-STENT RESTENOSIS; ISCHEMIC HEART DISEASE; LEG ISCHEMIA; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MOLECULAR TARGETED THERAPY; PROSTHESIS FAILURE; STENTS;

EID: 84875365035     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.10.008     Document Type: Article

References (110)

1. Alba R., et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114(5):965-971.
2. Alemany R., Curiel D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 2001, 8(17):1347-1353.
3. Bangalore S., et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012, 125(23):2873-2891.
4. Barouch D.H., et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011, 29(32):5203-5209.
5. Bergelson J.M., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275(5304):1320-1323.
6. Bhatt K., Mi Q.S., Dong Z. microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am. J. Physiol. Renal Physiol. 2011, 300(3):F602-F610.
7. BHF Coronary Heart Disease Satistics, 2010. http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001546.
8. Boettger T., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J. Clin. Invest. 2009, 119(9):2634-2647.
9. Bradley R.R., et al. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 2012, 86(1):625-629.
10. Bradshaw A.C., et al. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog. 2010, 6(10):e1001142.
11. Bradshaw, A.C., et al., in press. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J. Control. Release.
12. Carlisle R.C., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009, 113(9):1909-1918.
13. Caruso P., et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ. Res. 2012, 111(3):290-300.
14. Chase A.J., Newby A.C. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J. Vasc. Res. 2003, 40(4):329-343.
15. Cohen D.J., et al. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter. Cardiovasc. Interv. 2012, 79(2):198-209.
16. Coughlan L., et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010, 2(10):2290-2355.
17. Denby L., et al. Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol. Ther. 2007, 15(9):1647-1654.
18. Di Paolo N.C., et al. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 2009, 31(1):110-121.
19. Dollery C.M., et al. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999, 99(24):3199-3205.
20. Duffy M.R., et al. A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes. J. Virol. 2011, 85(20):10914-10919.
21. Duffy M.R., et al. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine (Lond.) 2012, 7(2):271-288.
22. Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J. Gene Med. 2007, 9(10):833-842.
23. Eisenstein E.L., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007, 297(2):159-168.
24. European Cardiovascular Disease Statistics, BHF, 2008. http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001443.
25. Fitzgibbon G.M., et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25years. J. Am. Coll. Cardiol. 1996, 28(3):616-626.
26. Gaggar A., Shayakhmetov D.M., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 2003, 9(11):1408-1412.
27. George S.J., et al. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 1998, 5(11):1552-1560.
28. George S.J., et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum. Gene Ther. 1998, 9(6):867-877.
29. George S.J., et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000, 101(3):296-304.
30. George S.J., et al. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 2011, 124(11 Suppl.):S135-S142.
31. Goldman S., et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J. Am. Coll. Cardiol. 2004, 44(11):2149-2156.
32. Haery C., Sachar R., Ellis S.G. Drug-eluting stents: the beginning of the end of restenosis?. Cleve. Clin. J. Med. 2004, 71(10):815-824.
33. Hedman M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107(21):2677-2683.
34. Hiltunen M.O., et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J. 2000, 14(14):2230-2236.
35. Hoch J.R., Stark V.K., Turnipseed W.D. The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J. Vasc. Surg. 1995, 22(1):51-58.
36. Holmes D.R., et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002, 106(10):1243-1250.
37. Hotchkiss J.W., et al. Trends in adult cardiovascular disease risk factors and their socio-economic patterning in the Scottish population 1995-2008: cross-sectional surveys. BMJ Open 2011, 1(1):e000176.
38. Jaschinski F., et al. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2. Curr. Pharm. Biotechnol. 2011, 12(12):2203-2213.
39. Jessup M., et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011, 124(3):304-313.
40. Ji R., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res. 2007, 100(11):1579-1588.
41. Jiang Z., et al. Established neointimal hyperplasia in vein grafts expands via TGF-beta-mediated progressive fibrosis. Am. J. Physiol. Heart Circ. Physiol. 2009, 297(4):H1200-H1207.
42. Kalyuzhniy O., et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(14):5483-5488.
43. Katsaros K.M., et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc. Interv. 2010, 3(1):90-97.
44. Koizumi N., et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J. Immunol. 2007, 178(3):1767-1773.
45. Kundi R., et al. Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc. Res. 2009, 84(2):326-335.
46. Kuusisto J., et al. Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study. Heart 2005, 91(5):576-582.
47. Laitinen M., et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther. 2000, 11(2):263-270.
48. Larochelle N., et al. Downregulation of CD46 during muscle differentiation: implications for gene transfer to human skeletal muscle using group B adenoviruses. Hum. Gene Ther. 2008, 19(2):133-142.
49. Law L.K., Davidson B.L. What does it take to bind CAR?. Mol. Ther. 2005, 12(4):599-609.
50. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75(5):843-854.
51. Leeper N.J., et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J. Cell. Physiol. 2011, 226(4):1035-1043.
52. Li E., et al. Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. J. Virol. 1998, 72(3):2055-2061.
53. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473(7347):317-325.
54. Liu X., et al. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J. Mol. Cell. Cardiol. 2012, 52(1):245-255.
55. Machlin E.S., Sarnow P., Sagan S.M. Combating hepatitis C virus by targeting microRNA-122 using locked nucleic acids. Curr. Gene Ther. 2012, 12(4):301-306.
56. Makinen K., et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 2002, 6(1):127-133.
57. Martin K., et al. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Ther. 2003, 8(3):485-494.
58. McDonald R.A., et al. MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovasc. Res. 2012, 93(4):594-604.
59. Mitra A.K., Agrawal D.K. In stent restenosis: bane of the stent era. J. Clin. Pathol. 2006, 59(3):232-239.
60. Motwani J.G., Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998, 97(9):916-931.
61. Muruve D.A., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452(7183):103-107.
62. Nabel E.G., et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(22):10759-10763.
63. Nemerow G.R. A new link between virus cell entry and inflammation: adenovirus interaction with integrins induces specific proinflammatory responses. Mol. Ther. 2009, 17(9):1490-1491.
64. Nemunaitis J., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 2006, 24(29):4721-4730.
65. Newby A.C. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul. Pharmacol. 2012, 56(5-6):232-244.
66. Nicklin S.A., et al. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000, 102(2):231-237.
67. Nicklin S.A., et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol. Ther. 2001, 4(6):534-542.
68. Nicol C.G., et al. Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Lett. 2009, 583(12):2100-2107.
69. Nikol S., et al. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J. Clin. Invest. 1992, 90(4):1582-1592.
70. Patterson L.J. The "STEP-wise" future of adenovirus-based HIV vaccines. Curr. Med. Chem. 2011, 18(26):3981-3986.
71. Porter K.E., et al. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Br. J. Surg. 1998, 85(10):1373-1377.
72. Puhakka H.L., et al. Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J. Vasc. Res. 2005, 42(5):361-367.
73. Rajagopalan S., et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am. Heart J. 2003, 145(6):1114-1118.
74. Raper S.E., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80(1-2):148-158.
75. Reynolds P.N., et al. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol. Ther. 2000, 2(6):562-578.
76. Rezaie A.R. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J. Biol. Chem. 2000, 275(5):3320-3327.
77. Rosenberg S.A., et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990, 323(9):570-578.
78. Russell W.C. Adenoviruses: update on structure and function. J. Gen. Virol. 2009, 90(Pt 1):1-20.
79. Schoggins J.W., Falck-Pedersen E. Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity. J. Virol. 2006, 80(21):10634-10644.
80. Schulick A.H., et al. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(12):6983-6988.
81. Seiradake E., et al. The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 2009, 5(1):e1000277.
82. Serruys P.W., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 2009, 360(10):961-972.
83. Sharony R., et al. Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(4):H1651-H1659.
84. Sluijter J.P., de Kleijn D.P., Pasterkamp G. Vascular remodeling and protease inhibition-bench to bedside. Cardiovasc. Res. 2006, 69(3):595-603.
85. Smith J.D., et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ. Res. 1999, 84(10):1212-1222.
86. Smith T.A., et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 2003, 14(8):777-787.
87. Sparano J.A., et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 2004, 22(23):4683-4690.
88. Stewart D.J., et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006, 13(21):1503-1511.
89. Stone G.W., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 2007, 356(10):998-1008.
90. Stone D., et al. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 2007, 81(9):4866-4871.
91. Strong J.P. Atherosclerosis in the young: risk and prevention. Hosp. Pract. (Minneap) 1999, 34(10):15-16. (19).
92. Tamai H., et al. Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am. Heart J. 1999, 138(5 Pt 1):968-975.
93. Teigler J.E., Iampietro M.J., Barouch D.H. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J. Virol. 2012, 86(18):9590-9598.
94. ten Dijke P., Arthur H.M. Extracellular control of TGFbeta signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 2007, 8(11):857-869.
95. Tian J., et al. Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J. Virol. 2009, 83(11):5648-5658.
96. Tranbaugh R.F., et al. Radial artery conduits improve long-term survival after coronary artery bypass grafting. Ann. Thorac. Surg. 2010, 90(4):1165-1172.
97. Tsai V., et al. Complement component C1q and anti-hexon antibody mediate adenovirus infection of a CAR-negative cell line. Viral Immunol. 2008, 21(4):469-476.
98. Tsai S., et al. TGF-beta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am. J. Physiol. Heart Circ. Physiol. 2009, 297(2):H540-H549.
99. Vigant F., et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. 2008, 16(8):1474-1480.
100. Waddington S.N., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132(3):397-409.
101. Wan S., et al. Vein graft failure: current clinical practice and potential for gene therapeutics. Gene Ther. 2012, 19(6):630-636.
102. Wang H., et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med. 2011, 17(1):96-104.
103. Wang Y.S., et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc. Res. 2012, 95(4):517-526.
104. Wickham T.J., et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73(2):309-319.
105. Wickham T.J., et al. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol. 1994, 127(1):257-264.
106. Wolff R.A., et al. Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. J. Vasc. Surg. 2005, 41(3):498-508.
107. Wolff R.A., et al. Transforming growth factor-beta1 antisense treatment of rat vein grafts reduces the accumulation of collagen and increases the accumulation of h-caldesmon. J. Vasc. Surg. 2006, 43(5):1028-1036.
108. Work L.M., et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol. Ther. 2004, 9(2):198-208.
109. Yamamoto K., et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000, 102(11):1308-1314.
110. Yeh R.W., et al. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation 2011, 124(14):1557-1564.